• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Authors » Charlie Passut

Charlie Passut

Articles

ARTICLES

survey results text

Survey: Fears of Postpandemic ‘Snap Back’ on Clinical Trial Innovations Misplaced

July 1, 2021
Charlie Passut
As the pandemic wanes, a new report shows that most sponsors and CROs plan to continue using the clinical trial innovations postpandemic, and that fears of a “snap back” to the status quo are misplaced. But the survey also found that sponsors and CROs have very different views on how prepared they are to deploy certain innovations for the long haul. Read More
Decentralization-360x240.png

Selective Use of Decentralization Methods Best Bet for Most Trials Postpandemic

June 7, 2021
Charlie Passut
For more than a year, sponsors have been working with some form of decentralized trials (DCT) and are seeing more clearly how some protocols are benefitting — and some not — from specific elements of decentralization. Read More
Reporting-360x240.png

FDA Has Long Way to Go to Correct Trial Reporting Noncompliance, Study Shows

June 7, 2021
Charlie Passut
When the FDA threatened penalties in April against a sponsor for failure to submit timely trial results to ClinicalTrials.gov, many saw it as a shot across the bow warning sponsors of the agency’s intention to get tough on violators of a rule intended to make trials more transparent and research findings more accessible to the industry and the public alike. Read More
COVID-19 race

Accelerated Trial Timelines Putting Increased Pressure on Sites

June 1, 2021
Charlie Passut
Accelerated timelines for clinical trial startup will become more the norm postpandemic, but different types of trials will find success at speed at different kinds of sites. Read More
Oncology-360x240.png

Clinical Trial Activity Stayed Historically High in 2020 Despite Pandemic, Especially in Oncology, IQVIA Says

May 24, 2021
Charlie Passut
Despite the pandemic, clinical trial activity remained historically high in 2020, especially in oncology, according to a new report by IQVIA. Clinical trial starts increased 8 percent in 2020, an annual growth rate on par with those observed since 2017. Read More
Protocol button

Use of Master Protocols Expected to Grow in Wake of FDA Guidance

May 24, 2021
Charlie Passut
The use of master protocols in the U.S. will likely increase and expand into more treatment areas now that the FDA has signaled support for the practice in a new final guidance for COVID-19 trials last week. Read More
Compensation-360x240.png

Sites Look to Compensate Trial Participants While Avoiding Undue Influence

May 24, 2021
Charlie Passut
Compensating clinical trial participants for their time, effort and risk is a practice commonly accepted by regulators and IRBs, although regulations do not specifically mention the concept. Instead, they require only that a trial’s informed consent process be free of any coercion or undue influence although many questions remain about what’s allowed and what isn’t. Read More
Clinical-Trial-Brainstorming

Clinical Trial Agreements Evolving as Postpandemic Era Gains Traction

May 17, 2021
Charlie Passut
As the pace of nonCOVID-19 trials picks up, some contentious issues are arising in the negotiation of clinical trial agreements (CTAs), partly due to what sites were willing to agree to at the height of the pandemic when most CTAs focused on COVID vaccines or treatments. Read More
FocusinRed-360x240.png

As the Pandemic Eases, Sites Focus On Improving Study Startup Times

May 10, 2021
Charlie Passut
Delays to study startup caused by the pandemic have eased with institutional sites now saying they’ve been able to reduce time needed for the process from six months on average to two or three months. Read More
Oncology-360x240.png

Oncology Trials Outpacing Rest of the Field in Complexity and Duration, Study Shows

May 10, 2021
Charlie Passut
Clinical trials in all therapeutic areas are increasing in complexity, but oncology trials are outstripping the rest of the field due to enrollment challenges, protocol deviations and a burgeoning amount of data that are adding months to their timelines. Read More
View All Articles by Charlie Passut

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing